Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Hepatitis C

  Free Subscription


Articles published in Eur J Gastroenterol Hepatol

Retrieve available abstracts of 49 articles:
HTML format



Single Articles


    September 2021
  1. EL KASSAS M, Abdeen N, Omran D, Alboraie M, et al
    Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis.
    Eur J Gastroenterol Hepatol. 2021 Sep 21. pii: 00042737-900000000-97142.
    PubMed     Abstract available


    July 2021
  2. ALEM SA, Eletreby R, Abdellatif Z, Ramadan A, et al
    Long-term clinical outcomes in sustained responders with chronic hepatitis C after treatment with direct-acting antivirals.
    Eur J Gastroenterol Hepatol. 2021 Jul 6. pii: 00042737-900000000-97183.
    PubMed     Abstract available


  3. EL RAY A, Fouad R, ElMakhzangy H, El Beshlawy M, et al
    Characterizing a cohort of Egyptian patients with acute-on-chronic liver failure.
    Eur J Gastroenterol Hepatol. 2021;33:1023-1028.
    PubMed     Abstract available


    April 2021
  4. HAYES KN, Burkard T, Weiler S, Tadrous M, et al
    Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase.
    Eur J Gastroenterol Hepatol. 2021 Apr 21. pii: 00042737-900000000-97232.
    PubMed     Abstract available


  5. YEO YH, Kam LY, Le MH, Jeong D, et al
    A population-based US study of hepatitis C diagnosis rate.
    Eur J Gastroenterol Hepatol. 2021 Apr 16. pii: 00042737-900000000-97245.
    PubMed     Abstract available


  6. KUMADA T, Toyoda H, Yasuda S, Tada T, et al
    Usefulness of serial FIB-4 score measurement for predicting the risk of hepatocarcinogenesis after hepatitis C virus eradication.
    Eur J Gastroenterol Hepatol. 2021 Apr 9. pii: 00042737-900000000-97256.
    PubMed     Abstract available


    March 2021
  7. SERWAH MA, Omar SA, Khedr MS, Abdel-Hamid AES, et al
    Occurrence and clinical characteristics of occult hepatitis C virus infection in hemodialysis units at Ismailia, Egypt.
    Eur J Gastroenterol Hepatol. 2021 Mar 12. pii: 00042737-900000000-97270.
    PubMed     Abstract available


    February 2021
  8. SAHIN M, Sucu P, Serin E, Yetim A, et al
    Serum fibrosis markers could aid in the prediction of factor for successful oral antiviral treatment in hepatitis C.
    Eur J Gastroenterol Hepatol. 2021 Feb 5. pii: 00042737-900000000-97302.
    PubMed     Abstract available


  9. SAUD LRC, Chagas AL, Maccali C, Pinto PVA, et al
    Hepatocellular carcinoma in patients coinfected with hepatitis B or C and HIV: more aggressive tumor behavior?
    Eur J Gastroenterol Hepatol. 2021 Feb 5. pii: 00042737-900000000-97300.
    PubMed     Abstract available


    January 2021
  10. EL-NAHAAS SM, Rady NH, Malek S, Serag K, et al
    Changes in serum interferon-gamma-inducible protein-10 levels and liver stiffness among chronic hepatitis C Egyptian patients in response to directly acting antiviral agents.
    Eur J Gastroenterol Hepatol. 2021 Jan 18. pii: 00042737-900000000-97309.
    PubMed     Abstract available


  11. EL KASSAS M, Alboraie M, El-Sayed M, Elbehiry S, et al
    Effect of disease stage and treatment outcomes on the dynamics of liver functions during and after treatment of hepatitis C with directly acting antivirals.
    Eur J Gastroenterol Hepatol. 2021 Jan 14. doi: 10.1097/MEG.0000000000002043.
    PubMed     Abstract available


  12. YILMAZ B, Kayadibi H, Yeniova AO, Koseoglu H, et al
    The age, bilirubin and albumin (ABA) index: a novel noninvasive index for predicting liver fibrosis in patients with chronic hepatitis C infection.
    Eur J Gastroenterol Hepatol. 2021;Publish Ahead of Print.
    PubMed     Abstract available


  13. PESTANA NF, Equi CMA, Gomes CP, Cardoso AC, et al
    Aminotransferase-to-platelet ratio index and Fibrosis-4 index score predict hepatic fibrosis evaluated by transient hepatic elastography in hepatitis C virus-infected hemodialysis patients.
    Eur J Gastroenterol Hepatol. 2021;Publish Ahead of Print.
    PubMed     Abstract available


    November 2020
  14. LASHEN SA, Metawea MI, Shaaban A
    Direct antiviral drugs in the treatment of hepatitis C-infected rheumatoid arthritis Egyptian cohort: safety and clinical impact.
    Eur J Gastroenterol Hepatol. 2020 Nov 30. doi: 10.1097/MEG.0000000000002015.
    PubMed     Abstract available


  15. RIAL-CRESTELO D, Sepulveda MA, Gonzalez-Gasca FJ, Geijo-Martinez P, et al
    Impact of interferon-free therapies in HIV/HCV co-infected patients on real clinical practice: results from a multicenter region-wide cohort study (2014-2018).
    Eur J Gastroenterol Hepatol. 2020 Nov 30. doi: 10.1097/MEG.0000000000002012.
    PubMed     Abstract available


  16. LITHY RM, Elbaz T, H Abdelmaksoud A, M Nabil M, et al
    Survival and recurrence rates of hepatocellular carcinoma after treatment of chronic hepatitis C using direct acting antivirals.
    Eur J Gastroenterol Hepatol. 2020 Nov 17. doi: 10.1097/MEG.0000000000001972.
    PubMed     Abstract available


  17. RUIZ I, Fourati S, Ahmed-Belkacem A, Rodriguez C, et al
    Real-world efficacy and safety of direct-acting antiviral drugs in patients with chronic hepatitis C and inherited blood disorders.
    Eur J Gastroenterol Hepatol. 2020 Nov 17. doi: 10.1097/MEG.0000000000002003.
    PubMed     Abstract available


    October 2020
  18. OMRAN M, Fouda M, Abdelwahab AO, Nabeel MM, et al
    P53 is a risk factor of de-novo hepatitis C-related hepatocellular carcinoma treated with direct-acting antivirals: a case-control study.
    Eur J Gastroenterol Hepatol. 2020 Oct 16. doi: 10.1097/MEG.0000000000001962.
    PubMed     Abstract available


    September 2020
  19. STEIN K, Stoehr A, Klinker H, Teuber G, et al
    Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
    Eur J Gastroenterol Hepatol. 2020 Sep 17. doi: 10.1097/MEG.0000000000001923.
    PubMed     Abstract available


    August 2020
  20. ABDO M, Rabiee A, Abdellatif Z, Abdel Alem S, et al
    Impact of sustained virological response on metabolic disorders in diabetic chronic hepatitis C virus patients after treatment with generic sofosbuvir and daclatasvir.
    Eur J Gastroenterol Hepatol. 2020 Aug 14. doi: 10.1097/MEG.0000000000001903.
    PubMed     Abstract available


  21. NUMAO H, Shimaya K, Kakuta A, Shibutani K, et al
    The utility of two-dimensional real-time shear wave elastography for assessing liver fibrosis in patients with chronic hepatitis C virus infection.
    Eur J Gastroenterol Hepatol. 2020 Aug 14. doi: 10.1097/MEG.0000000000001887.
    PubMed     Abstract available


  22. BEYAN C, Beyan E
    Mean platelet volume to platelet ratio may not be reliable to determine the severity of fibrosis in patients with chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2020;32:1067.
    PubMed    


  23. ELSADEK HM, Abdelbaser ES, Emara MH, Soliman HH, et al
    Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients.
    Eur J Gastroenterol Hepatol. 2020;32:1046-1053.
    PubMed     Abstract available


    July 2020
  24. GUAN X, Xing F, Li Y
    Alcohol consumption increases the incidence of hepatocellular carcinoma in patients with hepatitis B cirrhosis but not in patients with hepatitis C cirrhosis.
    Eur J Gastroenterol Hepatol. 2020 Jul 8. doi: 10.1097/MEG.0000000000001837.
    PubMed     Abstract available


  25. GARRIDO-ESTEPA M, Latasa P, Flores-Herrera J, Garcia Comas L, et al
    Hepatitis C and hepatitis C-related advanced liver disease hospitalisation trends before and after the Strategic Plan for Tackling Hepatitis C in the National Health System.
    Eur J Gastroenterol Hepatol. 2020 Jul 8. doi: 10.1097/MEG.0000000000001841.
    PubMed     Abstract available


  26. CHEN SH, Huang CL, Chiang IP, Chang TC, et al
    Liver fibrosis regression correlates with downregulation in liver angiogenesis in chronic hepatitis C through viral eradication.
    Eur J Gastroenterol Hepatol. 2020 Jul 8. doi: 10.1097/MEG.0000000000001833.
    PubMed     Abstract available


  27. MCPHAIL J, Sims OT, Guo Y, Wooten D, et al
    Fibrosis improvement in patients with HCV treated with direct-acting antivirals.
    Eur J Gastroenterol Hepatol. 2020 Jul 3. doi: 10.1097/MEG.0000000000001821.
    PubMed     Abstract available


    June 2020
  28. ABDEL MOEZ AT, El Hawary YA, Al Balakosy AM
    Can successful treatment by direct-acting antivirals improve depression in chronic HCV patients?
    Eur J Gastroenterol Hepatol. 2020 Jun 16. doi: 10.1097/MEG.0000000000001790.
    PubMed     Abstract available


  29. DA BL, Lourdusamy V, Kushner T, Dieterich D, et al
    Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus.
    Eur J Gastroenterol Hepatol. 2020 Jun 11. doi: 10.1097/MEG.0000000000001786.
    PubMed     Abstract available


    May 2020
  30. QIU LX, Liu YL, Lin W, Liu YR, et al
    Liver stiffness measurement is a potent predictor of histological fibrosis regression after hepatitis C virus clearance.
    Eur J Gastroenterol Hepatol. 2020 May 22. doi: 10.1097/MEG.0000000000001749.
    PubMed     Abstract available


  31. TANOGLU A
    Clinical utility of mean platelet volume and related scores for assessing the severity of hepatic fibrosis in chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2020;32:664-665.
    PubMed    


    April 2020
  32. HINRICHSEN H, Stoehr A, Cornberg M, Klinker H, et al
    Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry.
    Eur J Gastroenterol Hepatol. 2020 Apr 25. doi: 10.1097/MEG.0000000000001759.
    PubMed     Abstract available


    March 2020
  33. GONZALEZ-COLOMINAS E, Batlle M, Monge-Escartin I, Duran X, et al
    Impact of HCV cure with drug-acting antivirals in the use of concomitant medication and lipid profile: follow-up data 2 years after the sustained virological response.
    Eur J Gastroenterol Hepatol. 2020 Mar 16. doi: 10.1097/MEG.0000000000001714.
    PubMed     Abstract available


  34. CHUN HS, Kim BK, Park JY, Kim DY, et al
    Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2020;32:378-385.
    PubMed     Abstract available


    February 2020
  35. PERISETTI A, Laoveeravat P, Inamdar S, Tharian B, et al
    Hepatitis E virus infection in liver transplant recipients: a descriptive literature review.
    Eur J Gastroenterol Hepatol. 2020 Feb 21. doi: 10.1097/MEG.0000000000001682.
    PubMed     Abstract available


    January 2020
  36. ABDELSAMEEA E, Alsebaey A, Abdel-Razek W, Ehsan N, et al
    Elastography and serum markers of fibrosis versus liver biopsy in 1270 Egyptian patients with hepatitis C.
    Eur J Gastroenterol Hepatol. 2020 Jan 15. doi: 10.1097/MEG.0000000000001672.
    PubMed     Abstract available


    December 2019
  37. HASSANIN TM, Abdelraheem EM, Abdelhameed S, Abdelrazik M, et al
    Detection of hepatitis C virus core antigen as an alternative method for diagnosis of hepatitis C virus infection in blood donors negative for hepatitis C virus antibody.
    Eur J Gastroenterol Hepatol. 2019 Dec 31. doi: 10.1097/MEG.0000000000001647.
    PubMed     Abstract available


  38. RAMACHANDRAN J, Kaambwa B, Muller K, Haridy J, et al
    Cost effectiveness of treatment models of care for hepatitis C: the South Australian state-wide experience.
    Eur J Gastroenterol Hepatol. 2019 Dec 31. doi: 10.1097/MEG.0000000000001659.
    PubMed     Abstract available


  39. LIONS C, Laroche H, Zaegel-Faucher O, Ressiot E, et al
    Hepatitis C virus-microelimination program and patient trajectories after hepatitis C virus cure in an outpatient HIV clinical unit.
    Eur J Gastroenterol Hepatol. 2019 Dec 16. doi: 10.1097/MEG.0000000000001640.
    PubMed     Abstract available


  40. DARWEESH SK, Yosry A, Salah M, Zayed N, et al
    Acoustic radiation forced impulse-based splenic prediction model using data mining for the noninvasive prediction of esophageal varices in hepatitis C virus advanced fibrosis.
    Eur J Gastroenterol Hepatol. 2019;31:1533-1539.
    PubMed     Abstract available


    November 2019
  41. SHOUSHA HI, Saad Y, Saleh DA, Dabes H, et al
    Simple predictors of nonresponse to direct-acting antivirals in chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2019 Nov 25. doi: 10.1097/MEG.0000000000001612.
    PubMed     Abstract available


  42. TOSON EA, Shiha GE, El-Sharkawy AM, El-Mezayen HA, et al
    Diagnostic performance of extrinsic apoptosis pathway in hepatitis C virus patients: apoptosis fibrosis crosstalk.
    Eur J Gastroenterol Hepatol. 2019 Nov 14. doi: 10.1097/MEG.0000000000001603.
    PubMed     Abstract available


  43. GOZDAS HT, Ince N
    Elevated mean platelet volume to platelet ratio predicts advanced fibrosis in chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2019 Nov 7. doi: 10.1097/MEG.0000000000001599.
    PubMed     Abstract available


  44. SLIEM HA, Salem AS, Hussien WM, El Sayed HRA, et al
    Arterial wall structural changes in noncirrhotic chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2019;31:1432-1438.
    PubMed     Abstract available


  45. WIEGAND J, Buggisch P, Mauss S, Boeker KHW, et al
    Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
    Eur J Gastroenterol Hepatol. 2019;31:1424-1431.
    PubMed     Abstract available


    October 2019
  46. EL-KHAYAT H, Kamal EM, Mahmoud H, Gomaa A, et al
    Retreatment of chronic hepatitis C virus genotype-4 patients after non-structural protein 5A inhibitors' failure: efficacy and safety of different regimens.
    Eur J Gastroenterol Hepatol. 2019 Oct 30. doi: 10.1097/MEG.0000000000001581.
    PubMed     Abstract available


  47. HEIL J, Soufidi K, Stals F, Frantzen H, et al
    Retrieval and re-evaluation of previously diagnosed chronic hepatitis C infections lost to medical follow-up in the Netherlands.
    Eur J Gastroenterol Hepatol. 2019 Oct 30. doi: 10.1097/MEG.0000000000001593.
    PubMed     Abstract available


  48. TACHI Y, Hirai T, Kojima Y, Tachino H, et al
    Diagnostic performance of real-time tissue elastography in chronic hepatitis C patients with sustained virological response.
    Eur J Gastroenterol Hepatol. 2019 Oct 30. doi: 10.1097/MEG.0000000000001539.
    PubMed     Abstract available


    September 2019
  49. ABBAS OM, Khalifa KAE, Makhlouf MM, Osman NF, et al
    Influence of esophageal variceal bleeding on iron status in chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2019 Sep 16. doi: 10.1097/MEG.0000000000001547.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: